Bayer’s Technical Battle at the 200-Day Line Gets Reinforcement from Agriculture AI and Kidney Drug Progress

Bayer shares entered the week walking a tightrope just above a key long-term trendline, but the company’s pipeline and digital agriculture business are providing a fundamental counterweight that could help the stock hold its ground. After closing at €36.16 on Friday and breaching the 200-day moving average near €35.80, the stock slipped to €35.88 by Monday — only 11 cents above the same line, now calculated at €35.84. The 0.19% daily decline came in a weak overall market buffeted by geopolitical tensions and rising bond yields, lending the move more weight than the small percentage suggests.

The pullback represents a textbook retest of the 200-day line as support. On June 3, the stock crossed that average to the upside, and the current dip is testing whether that breakout was genuine. Chartists view a sustained close below €35.84 as a shift from a constructive to a neutral technical picture, which could invite additional selling pressure. If the level holds, the recovery from the summer low remains credible.

What gives the bulls ammunition beyond chart patterns are two distinct fundamental developments. Bayer’s “Climate Fieldview” platform — billed as the world’s largest digital farm platform — aggregates machine, soil, weather and satellite data to generate planting recommendations. The company says users see an 8% yield increase per hectare. At an EV/Ebitda multiple of roughly 8, the stock trades at a meaningful discount to pure-play ag-tech and food companies, and analysts see revaluation potential if the digital business continues to scale.

On the pharmaceutical side, Bayer presented Phase III data from the FIND-CKD study at the 63rd ERA Congress on Friday. The results showed that Finerenone significantly slows the decline of kidney function in patients with non-diabetic chronic kidney disease, substantially broadening the drug’s potential market. Finerenone had previously been positioned primarily for diabetic indications, and this expansion provides a counterbalance to the ongoing legal overhang from U.S. glyphosate litigation.

Should investors sell immediately? Or is it worth buying Bayer?

UBS remains a buyer with a €52 price target. In the first quarter of 2026, Bayer posted revenue of €13.41 billion and adjusted earnings per share of €2.71, beating expectations. The bank’s conviction reflects a view that operational progress and pipeline wins can eventually outweigh the debt burden and U.S. legal risks.

Still, the technical path is far from clear. The first overhead hurdle is the 50-day moving average, which stood at €38.35 by Monday’s close — slightly below the €38.39 level noted at the end of last week. A return above that line would meaningfully ease the short-term downtrend. Beyond that, the 100-day average at €40.44 represents the next serious resistance, while the 52-week high of €49.93 from February 17 remains distant.

The RSI on a 14-day basis sits at 42.3, signaling neither overbought nor deeply oversold conditions. The annualized 30-day volatility is 36.97%, keeping large swings a live possibility in a jittery macro environment. The 52-week low of €25.09 offers a wide safety cushion, but in the near term all attention centers on the €35.84 line.

For today’s session, that mark is the concrete test. A close below it would technically sour the outlook. Above it, Bayer remains in retest mode with the 50-day average at €38.35 as the next serious upside target. Whether the combination of a digital agriculture growth story and a broadened kidney drug franchise can tip the balance remains the key question for the weeks ahead.